About Us

Ping Mu, Ph.D.

Ping Mu, Ph.D.
Principal Investigator

Ping received his B.S. in Biotechnology from Peking University, Beijing, China. He earned his Ph.D. in Biomedical Sciences (Cancer Biology) from Weill Cornell Medical College, where he worked with Dr. Andrea Ventura. Ping identified a microRNA called miR-19 as a crucial oncogenic driver of Myc-driven B cell lymphoma and prostate cancer. This work provided the key rationale for targeting miR-19 to treat these two cancers

In 2013, Ping joined the laboratory of Dr. Charles L. Sawyers as a postdoctoral fellow at Memorial Sloan Kettering Cancer Center, New York. There, he identified a novel mechanism of antiandrogen resistance in prostate cancer mediated by increased lineage plasticity, or “identity fraud”. This lineage plasticity is enabled by the activation of SOX2 and can be reversed by SOX2 inhibition, which raises the hope that appropriate clinical intervention of lineage plasticity could prevent or overcome resistance. During his postdoctoral training, Ping successfully conducted an in vivo library screen based on shRNA; this screen identified several candidate genes that confer resistance to antiandrogen therapy. Elucidating the mechanisms by which these genes confer resistance will help us understand antiandrogen resistance and possibly identify novel biomarkers.

In 2018, Ping joined the faculty at UT Southwestern as an assistant professor in the Department of Molecular Biology.

Ping is the recipient of a DoD PCRP Postdoctoral Training award (2014), a NIH K99/R00 Pathway to Independence award (2017), a Prostate Cancer Foundation Young Investigator award (2017), and a Cancer Prevention Research Institute of Texas (CPRIT) Recruitment of First-Time, Tenure-Track Faculty Member award (2017). He is also the Deborah and W.A. “Tex” Moncrief, Jr. Scholar in Medical Research Award (2018), and recipient of a DoD Idea Development Award (2018).

Dr. Ping Mu discusses how cancer disguises itself, in a fascinating comparison to identity theft, in this video by the Prostate Cancer Foundation.